| Literature DB >> 31035056 |
Ana Cláudia Santos1, Irina Pereira2, Miguel Pereira-Silva3, Laura Ferreira3, Mariana Caldas3, Mar Collado-González4, Mariana Magalhães2, Ana Figueiras2, António J Ribeiro5, Francisco Veiga2.
Abstract
Resveratrol (RES), also known as 3,5,4'-trihydroxystilbene, is a polyphenolic phytoalexin that has been widely researched in the past decade due to its recognized numerous biological activities. Despite the potential benefits of RES, its effective use is limited due to its poor solubility, photosensitivity and rapid metabolism, which strongly undermine RES bioavailability and bioactivity. Thereby, recently, nanotechnology appeared as a potential strategy to circumvent RES physicochemical and pharmacokinetics constrains. However, only few studies have addressed the crucial in vivo suitability of the developed delivery systems to improve RES efficacy. Facing this scenario, in the present review, it is intended to present and discuss the in vivo resveratrol bioavailability and bioactivity, following its encapsulation or conjugation in nanotechnology-based carriers, contemplating their pharmacokinetics effectiveness.Entities:
Keywords: Bioactivity; Bioavailability; In vivo; Nanocarriers; Nanoencapsulation; Nanoformulations; Nanoparticles; Nanotechnology; Resveratrol
Year: 2019 PMID: 31035056 DOI: 10.1016/j.colsurfb.2019.04.030
Source DB: PubMed Journal: Colloids Surf B Biointerfaces ISSN: 0927-7765 Impact factor: 5.268